subscribeSubscribe
SIKLOS® (hydroxyurea) is now covered by State Medicaid programs in 19 states

SIKLOS® (hydroxyurea) is now covered by State Medicaid programs in 19 states
GLOBENEWSWIRE
21 Sep 2023
Share Share
EMA Approves OXBRYTA in EU to Target the Cause of SCD

EMA Approves OXBRYTA in EU to Target the Cause of SCD
PRNEWSWIRE
25 Feb 2022
Share Share
EAMS Scientific Opinion Awarded to Voxelotor for Haemolytic Anaemia Due to SCD

EAMS Scientific Opinion Awarded to Voxelotor for Haemolytic Anaemia Due to SCD
GLOBENEWSWIRE
27 Jan 2022
Share Share
Positive CHMP opinion for sickle cell disease anaemia tablet

Positive CHMP opinion for sickle cell disease anaemia tablet
PHARMAFILE
20 Dec 2021
Share Share
NICE turns down Novartis` Adakveo

NICE turns down Novartis` Adakveo
Selina McKee PHARMATIMES
27 Nov 2020
Share Share
Novartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent

Novartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent
NOVARTIS
30 Oct 2020
Share Share
Siklos®, the first and only hydroxyurea-based treatment for pediatric patients

Siklos®, the first and only hydroxyurea-based treatment for pediatric patients
PRNEWSWIRE
19 Oct 2020
Share Share
Leading Pharma`s Generic Hydroxyurea Receives Approval In US

Leading Pharma`s Generic Hydroxyurea Receives Approval In US
FDA
11 Apr 2020
Share Share
‘Revolutionary’ liquid sickle cell treatment unveiled

‘Revolutionary’ liquid sickle cell treatment unveiled
Anna Smith PHARMATIMES
25 Oct 2019
Share Share
Siklos` hydroxyurea-based Tx for Pediatric Pts now available

Siklos` hydroxyurea-based Tx for Pediatric Pts now available
PR NEWSWIRE
20 Aug 2018
Share Share